Paul Neumann
Albany College of Pharmacy and Health Sciences
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Paul Neumann.
BJUI | 2008
Carmin Kalorin; Anita Mannikarottu; Paul Neumann; Robert E. Leggett; Joshua Weisbrot; Arnold Johnson; Barry A. Kogan; Robert M. Levin
To measure the degree to which partial bladder outlet obstruction (PBOO) results in oxidative bladder damage, which subcellular components of the bladder are affected and whether these changes correlate with bladder function.
PLOS ONE | 2012
Amy Barton Pai; Heena Patel; Alexander J. Prokopienko; Hiba Al-Saffar; Nancy Gertzberg; Paul Neumann; Anjoli Punjabi; Arnold Johnson
Tunneled central venous catheters (TCVCs) are used for dialysis access in 82% of new hemodialysis patients and are rapidly colonized with Gram-positive organism (e.g. Staphylococcus aureus) biofilm, a source of recurrent infections and chronic inflammation. Lipoteichoic acid (LTA), a cell wall ribitol polymer from Gram-positive organisms, mediates inflammation through the Toll-like receptor 2 (TLR2). The effect of LTA on lung endothelial permeability is not known. We tested the hypothesis that LTA from Staphylococcus aureus induces alterations in the permeability of pulmonary microvessel endothelial monolayers (PMEM) that result from activation of TLR2 and are mediated by reactive oxygen/nitrogen species (RONS). The permeability of PMEM was assessed by the clearance rate of Evans blue-labeled albumin, the activation of the TLR2 pathway was assessed by Western blot, and the generation of RONS was measured by the fluorescence of oxidized dihydroethidium and a dichlorofluorescein derivative. Treatment with LTA or the TLR2 agonist Pam(3)CSK(4) induced significant increases in albumin permeability, IκBα phosphorylation, IRAK1 degradation, RONS generation, and endothelial nitric oxide synthase (eNOS) activation (as measured by the p-eNOSser1177:p-eNOSthr495 ratio). The effects on permeability and RONS were effectively prevented by co-administration of the superoxide scavenger Tiron, the peroxynitrite scavenger Urate, or the eNOS inhibitor L-NAME and these effects as well as eNOS activation were reduced or prevented by pretreatment with an IRAK1/4 inhibitor. The results indicate that the activation of TLR2 and the generation of ROS/RNS mediates LTA-induced barrier dysfunction in PMEM.
PLOS ONE | 2017
Xianlong Gao; Kristin C. Hicks; Paul Neumann; Tarun B. Patel
Receptor Tyrosine Kinase (RTK) signaling plays a major role in tumorigenesis and normal development. Sprouty2 (Spry2) attenuates RTK signaling and inhibits processes such as angiogenesis, cell proliferation, migration and survival, which are all upregulated in tumors. Indeed in cancers of the liver, lung, prostate and breast, Spry2 protein levels are markedly decreased correlating with poor patient prognosis and shorter survival. Thus, it is important to understand how expression of Spry2 is regulated. While prior studies have focused on the post-translation regulation of Spry2, very few studies have focused on the transcriptional regulation of SPRY2 gene. Here, we demonstrate that in the human hepatoma cell line, Hep3B, the transcription of SPRY2 is inhibited by the transcription regulating hypoxia inducible factors (HIFs). HIFs are composed of an oxygen regulated alpha subunit (HIF1α or HIF2α) and a beta subunit (HIF1β). Intriguingly, silencing of HIF1α and HIF2α elevates SPRY2 mRNA and protein levels suggesting HIFs reduce the transcription of the SPRY2 promoter. In silico analysis identified ten hypoxia response elements (HREs) in the proximal promoter and first intron of SPRY2. Using chromatin immunoprecipitation (ChIP), we show that HIF1α/2α bind near the putative HREs in the proximal promoter and intron of SPRY2. Our studies demonstrated that not only is the SPRY2 promoter methylated, but silencing HIF1α/2α reduced the methylation. ChIP assays also showed DNA methyltransferase1 (DNMT1) binding to the proximal promoter and first intron of SPRY2 and silencing HIF1α/2α decreased this association. Additionally, silencing of DNMT1 mimicked the HIF1α/2α silencing-mediated increase in SPRY2 mRNA and protein. While simultaneous silencing of HIF1α/2α and DNMT1 increased SPRY2 mRNA a little more, the increase was not additive suggesting a common mechanism by which DNMT1 and HIF1α/2α regulate SPRY2 transcription. Together these data suggest that the transcription of SPRY2 is inhibited by HIFs, in part, via DNMT1- mediated methylation.
American Journal of Physiology-lung Cellular and Molecular Physiology | 2006
Paul Neumann; Nancy Gertzberg; Erin Vaughan; Joshua Weisbrot; Renee Woodburn; William Lambert; Arnold Johnson
American Journal of Physiology-lung Cellular and Molecular Physiology | 1997
Thomas J. Ferro; Nancy Gertzberg; L. Selden; Paul Neumann; Arnold Johnson
American Journal of Respiratory Cell and Molecular Biology | 2000
Nancy Gertzberg; Richard Clements; Ilona Jaspers; Thomas J. Ferro; Paul Neumann; Eliezer Flescher; Arnold Johnson
American Journal of Physiology-regulatory Integrative and Comparative Physiology | 2007
Wei-Yu Lin; Robert M. Levin; Paul Chichester; Robert E. Leggett; Yung-Shun Juan; Arnold Johnson; Paul Neumann; Catherine Whitbeck; Ahmet Guven; Barry A. Kogan; Anita Mannikarottu
Molecular and Cellular Biochemistry | 2013
Connor M. Callaghan; Arnold Johnson; Paul Neumann; Robert E. Leggett; Catherine Schuler; Robert M. Levin
American Journal of Physiology-lung Cellular and Molecular Physiology | 2007
Nancy Gertzberg; Tina Gurnani; Paul Neumann; Anne-Kay Forbes; Natacha Jean-Louis; Arnold Johnson
Pulmonary Pharmacology & Therapeutics | 2013
Paul Neumann; Hiba Al-Saffar; Nancy Gertzberg; Arnold Johnson